申请人:Merck & Co., Inc.
公开号:US06043358A1
公开(公告)日:2000-03-28
Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, restenosis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, osteoarthritis, rheumatoid arthritis, septic arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.
本文披露了化合物I式及其药用盐,在治疗一氧化氮合酶介导的疾病和紊乱方面具有实用性,包括神经退行性疾病、胃肠运动障碍和炎症。这些疾病和紊乱包括低血压、脓毒性休克、毒性休克综合征、血液透析、IL-2治疗(如在癌症患者中)、虚弱、免疫抑制(如在移植治疗中)、自身免疫和/或炎症指示,包括晒伤、湿疹或银屑病,以及呼吸系统疾病,如支气管炎、哮喘、氧化剂诱导的肺损伤和急性呼吸窘迫综合征(ARDS)、肾小球肾炎、再狭窄、病毒感染的炎症后遗症、心肌炎、心力衰竭、动脉粥样硬化、骨关节炎、类风湿性关节炎、脓毒性关节炎、慢性或炎症性肠病、溃疡性结肠炎、克罗恩病、系统性红斑狼疮(SLE)、眼部疾病,如眼压增高、视网膜炎和葡萄膜炎、1型糖尿病、胰岛素依赖型糖尿病和囊性纤维化。